Second, although PD-L1 its expression status was closely associated with patient prognosis, the therapeutic effect of anti-PD-L1 mAbs in Xp11.2 RCC patients was not evaluated because these drugs are not yet available in China. This evidence concerns the gene CD274 and renal cell carcinoma.